Both albiglutide and dulaglutide received FDA approval for the treatment of T2DM in 2014, with dulaglutide having an additional indication since 2020 to reduce the risk of major adverse cardiovascular events (MACE) in adults with T2DM and established cardiovascular disease or multiple cardiovascular risk factors [ Table 2 ]
CLINICALLY-BACKED INGREDIENTS THAT WORK We use only the best, research-backed ingredients to support your GLP-1 lifestyle
Additionally, we are working to apply our TransCon technology platform in additional therapeutic areas such as metabolic diseases, where we believe we have designed a potentially best-in-class, once-monthly glucagon-like peptide 1 (GLP-1) product
19 BronP
Al-Temimi AA, Al-Mossawi AE, Al-Hilifi SA, Korma SA, Esatbeyoglu T, Rocha JM, Agarwal V
Depending on the solution used, at least 1cc of solution is utilized at the common extensor tendon attachment at the lateral epicondyle